23andMe Holdings: 23Me-00610 monotherapy continues to demonstrate acceptable safety and tolerability.
23Andme控股公司：23Me-00610单药疗法继续展示可接受的安全性和耐受性
23andMe Holdings: 23Me-00610 monotherapy continues to demonstrate acceptable safety and tolerability.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.